Hua Er Jie Jian Wen·2025-07-14 01:25Group 1 - The core point of the news is that President Trump has threatened pharmaceutical companies with a potential 200% tariff on imported drugs, but the market has reacted calmly due to the provided grace period for companies to adjust [1][2] - The grace period of "one to one and a half years" allows pharmaceutical companies ample time to stockpile and shift production, significantly reducing investor concerns [1][2] - Major pharmaceutical companies are already taking proactive measures, such as stockpiling drugs and increasing domestic production investments, indicating that industry confidence remains intact despite tariff threats [1][3] Group 2 - The grace period could extend until 2027, and companies may further extend their response time to 2028 through stockpiling, providing a strategic planning window for long-term adjustments [2] - The pharmaceutical industry is accelerating stockpiling, with hormone drug exports from Ireland to the U.S. valued at $36 billion this year, more than double last year's total [3] - Companies like Eli Lilly are investing heavily in U.S. manufacturing, with a $27 billion expansion plan, and tax incentives from Trump's "Big Beautiful Plan" are helping to mitigate the costs of establishing new facilities [3]